Judith Favier

List of Publications by Year
in descending order

97 papers	8,509 citations	50276 46 h-index	43889 91 g-index
113 all docs	113 docs citations	113 times ranked	7540 citing authors

#	Article	IF	Citations
1	International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma. Journal of Medical Genetics, 2022, 59, 785-792.	3.2	5
2	Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. Modern Pathology, 2022, 35, 352-360.	5.5	33
3	Persistent Properties of a Subpopulation of Cancer Cells Overexpressing the Hedgehog Receptor Patched. Pharmaceutics, 2022, 14, 988.	4.5	2
4	Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 459-471.	3.6	6
5	Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1301-e1315.	3.6	10
6	Sunitinib-induced cardiac hypertrophy and the endothelin axis. Theranostics, 2021, 11, 3830-3838.	10.0	7
7	Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate. Cancer Research, 2021, 81, 3480-3494.	0.9	26
8	An update on adult forms of hereditary pheochromocytomas and paragangliomas. Current Opinion in Oncology, 2021, 33, 23-32.	2.4	9
9	Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paragangliomaâ€"a retrospective and prospective study. Modern Pathology, 2020, 33, 57-64.	5.5	30
10	Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 898-907.	3.6	11
11	Succinate dehydrogenase deficiency in a chromaffin cell model retains metabolic fitness through the maintenance of mitochondrial NADH oxidoreductase function. FASEB Journal, 2020, 34, 303-315.	0.5	17
12	Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1510-1517.	6.4	22
13	An overview of 20Âyears of genetic studies in pheochromocytoma and paraganglioma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101416.	4.7	106
14	Concurrent imaging of vascularization and metabolism in a mouse model of paraganglioma under anti-angiogenic treatment. Theranostics, 2020, 10, 3518-3532.	10.0	12
15	Germline mutations in the new E1â€™ cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. Journal of Medical Genetics, 2020, 57, 752-759.	3.2	12
16	TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2Î±-Driven Mesenchymal Transition. Cell Reports, 2020, 30, 4551-4566.e7.	6.4	49
17	Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas. Endocrine-Related Cancer, 2020, 27, R451-R463.	3.1	22
18	Overexpression of miRâ€483â€5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma/paraganglioma. Clinical and Translational Medicine, 2020, 10, e260.	4.0	4

#	Article	IF	Citations
19	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	10.0	54
20	Evolutionarily conserved susceptibility of the mitochondrial respiratory chain to SDHI pesticides and its consequence on the impact of SDHIs on human cultured cells. PLoS ONE, 2019, 14, e0224132.	2.5	43
21	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	2.8	24
22	Emerging molecular markers of metastatic pheochromocytomas and paragangliomas. Annales D'Endocrinologie, 2019, 80, 159-162.	1.4	15
23	Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. Journal of Medical Genetics, 2019, 56, 513-520.	3.2	60
24	Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1109-1118.	3.6	82
25	Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2019, 25, 760-770.	7.0	82
26	Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas. Cancer Research, 2018, 78, 1914-1922.	0.9	96
27	Simultaneous positron emission tomography and ultrafast ultrasound for hybrid molecular, anatomical and functional imaging. Nature Biomedical Engineering, 2018, 2, 85-94.	22.5	44
28	Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis. Cell and Tissue Research, 2018, 372, 379-392.	2.9	16
29	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
30	Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. Science Signaling, 2017, 10, .	3.6	35
31	Risk assessment of maternally inheritedSDHDparaganglioma and phaeochromocytoma. Journal of Medical Genetics, 2017, 54, 125-133.	3.2	37
32	The mTORC1 Complex Is Significantly Overactivated in <i>SDHX</i>-Mutated Paragangliomas. Neuroendocrinology, 2017, 105, 384-393.	2.5	10
33	Mitochondrial Deficiencies in the Predisposition to Paraganglioma. Metabolites, 2017, 7, 17.	2.9	21
34	Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma. Oncotarget, 2017, 8, 51050-51057.	1.8	9
35	The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4764-4768.	3.6	16
36	Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene, 2016, 35, 1080-1089.	5.9	50

#	Article	IF	Citations
37	In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma. Clinical Cancer Research, 2016, 22, 1120-1129.	7.0	54
38	From Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma. Molecular and Cellular Endocrinology, 2016, 421, 40-48.	3.2	34
39	Models of pheochromocytoma: what's on the horizon?. International Journal of Endocrine Oncology, 2015, 2, 171-174.	0.4	2
40	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	5.5	176
41	SDHD Immunohistochemistry: A New Tool to ValidateSDHxMutations in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E287-E291.	3.6	45
42	Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255.	3.9	25
43	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	7.0	53
44	Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nature Communications, 2015, 6, 8784.	12.8	169
45	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6044.	12.8	153
46	Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nature Reviews Endocrinology, 2015, 11, 101-111.	9.6	396
47	Vascular Pattern Analysis for the Prediction of Clinical Behaviour in Pheochromocytomas and Paragangliomas. PLoS ONE, 2015, 10, e0121361.	2.5	14
48	Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget, 2015, 6, 32955-32965.	1.8	52
49	A MEN1 syndrome with a paraganglioma. European Journal of Human Genetics, 2014, 22, 283-285.	2.8	23
50	Peritoneal Implantation of Pheochromocytoma Following Tumor Capsule Rupture During Surgery. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2681-E2685.	3.6	33
51	Vascular Endothelial Growth Factor-A Is Associated with Chronic Mountain Sickness in the Andean Population. High Altitude Medicine and Biology, 2014, 15, 146-154.	0.9	16
52	SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer, 2014, 135, 2711-2720.	5.1	155
53	Unsuspected task for an old team: Succinate, fumarate and other Krebs cycle acids in metabolic remodeling. Biochimica Et Biophysica Acta - Bioenergetics, 2014, 1837, 1330-1337.	1.0	66
54	Mosaicism inHIF2A-Related Polycythemia-Paraganglioma Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E369-E373.	3.6	87

#	Article	IF	Citations
55	Oncometabolitesâ€driven tumorigenesis: From genetics to targeted therapy. International Journal of Cancer, 2014, 135, 2237-2248.	5.1	119
56	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Human Molecular Genetics, 2014, 23, 2440-2446.	2.9	316
57	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell, 2013, 23, 739-752.	16.8	606
58	Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused by SDHB Gene Mutations. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E954-E962.	3.6	87
59	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics, 2012, 21, 5397-5405.	2.9	126
60	HIF2AMutations in Paraganglioma with Polycythemia. New England Journal of Medicine, 2012, 367, 2161-2162.	27.0	59
61	A Decade (2001-2010) of Genetic Testing for Pheochromocytoma and Paraganglioma. Hormone and Metabolic Research, 2012, 44, 359-366.	1.5	103
62	La gÃ©nÃ©tique des paragangliomes. Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale, 2012, 129, 357-360.	0.0	0
63	The genetics of paragangliomas. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2012, 129, 315-318.	0.7	34
64	Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2012, 23, 34-42.	9.0	75
65	Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics, 2011, 20, 3974-3985.	2.9	266
66	SDHA Immunohistochemistry Detects Germline SDHA Gene Mutations in Apparently Sporadic Paragangliomas and Pheochromocytomas. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1472-E1476.	3.6	257
67	A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. European Journal of Endocrinology, 2011, 164, 141-145.	3.7	46
68	Rapid determination of tricarboxylic acid cycle enzyme activities in biological samples. BMC Biochemistry, 2010, 11, 5.	4.4	26
69	SDHA is a tumor suppressor gene causing paraganglioma. Human Molecular Genetics, 2010, 19, 3011-3020.	2.9	604
70	Pheochromocytomas: The (pseudo)-hypoxia hypothesis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 957-968.	4.7	94
71	The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas. PLoS ONE, 2009, 4, e7094.	2.5	203
72	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology, The, 2009, 10, 764-771.	10.7	477

#	Article	IF	Citations
73	RECENT ADVANCES IN THE GENETICS OF PHAEOCHROMOCYTOMA AND FUNCTIONAL PARAGANGLIOMA. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 376-379.	1.9	55
74	Apports de COMETE Ã la gÃ©nÃ©tique du phÃ©ochromocytome. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 105-116.	0.0	1
75	HIF2Î± reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma. BMC Cancer, 2007, 7, 139.	2.6	33
76	Role of MSK1 in the signaling pathway leading to VEGF-mediated PAF synthesis in endothelial cells. Vascular Pharmacology, 2006, 45, e130.	2.1	0
77	Role of MSK1 in the signaling pathway leading to VEGF-mediated PAF synthesis in endothelial cells. Journal of Cellular Biochemistry, 2006, 98, 1095-1105.	2.6	9
78	Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. American Journal of Physiology - Cell Physiology, 2006, 291, C1114-C1120.	4.6	95
79	Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo. Blood, 2005, 105, 103-110.	1.4	59
80	Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood, 2005, 105, 1523-1530.	1.4	159
81	Succinate dehydrogenase deficiency in human. Cellular and Molecular Life Sciences, 2005, 62, 2317-2324.	5.4	79
82	Critical overexpression of thrombospondin 1 in chronic leg ischaemia. Journal of Pathology, 2005, 207, 358-366.	4.5	48
83	Mitochondrial succinate is instrumental for HIF1Î± nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Human Molecular Genetics, 2005, 14, 3263-3269.	2.9	146
84	Hereditary Paraganglioma/Pheochromocytoma and Inherited Succinate Dehydrogenase Deficiency. Hormone Research in Paediatrics, 2005, 63, 171-179.	1.8	57
85	VEGF-A-MEDIATED ENDOTHELIAL P-SELECTIN TRANSLOCATION AND NEUTROPHIL ADHESION TO ENDOTHELIAL CELLS: ROLE OF VEGF RECEPTORS AND ENDOGENOUS PAF SYNTHESIS.. Cardiovascular Pathology, 2004, 13, 113.	1.6	0
86	VEGF-mediated endothelial P-selectin translocation: role of VEGF receptors and endogenous PAF synthesis. Blood, 2004, 103, 3789-3797.	1.4	50
87	THE HIF-PATHWAY, NEW CANDIDATE GENES FOR PARAGANGLIOMA AND/OR PHEOCHROMOCYTOMA?. Journal of Hypertension, 2004, 22, S77.	0.5	0
88	Angiopoietin-Like 4 Is a Proangiogenic Factor Produced during Ischemia and in Conventional Renal Cell Carcinoma. American Journal of Pathology, 2003, 162, 1521-1528.	3.8	287
89	Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research, 2003, 63, 5615-21.	0.9	409
90	Functional Consequences of aSDHBGene Mutation in an Apparently Sporadic Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4771-4774.	3.6	210

#	Article	IF	Citations
91	Angiogenesis and Vascular Architecture in Pheochromocytomas. American Journal of Pathology, 2002, 161, 1235-1246.	3.8	137
92	IN SITU HYBRIDIZATION AND IMMUNOGOLD LOCALIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 ON THE PERICYTES OF THE CHICK CHORIOALLANTOIC MEMBRANE. Cytokine, 2002, 17, 262-265.	3.2	10
93	The R22X Mutation of the SDHD Gene in Hereditary Paraganglioma Abolishes the Enzymatic Activity of Complex II in the Mitochondrial Respiratory Chain and Activates the Hypoxia Pathway. American Journal of Human Genetics, 2001, 69, 1186-1197.	6.2	339
94	Coexpression of endothelial PAS protein 1 with essential angiogenic factors suggests its involvement in human vascular development. Developmental Dynamics, 2001, 222, 377-388.	1.8	39
95	Paragangliome hÃ©rÃ©ditaire : identification d'une nouvelle mutation du gÃ¨ne SDHD impliquÃ© dans la rÃ©ponse Ã l'hypoxie. Revue De Medecine Interne, 2000, 21, 502.	1.0	0
96	Cloning and expression pattern of EPAS1 in the chicken embryo. FEBS Letters, 1999, 462, 19-24.	2.8	46
97	Orbital Nonchromaffin Paraganglioma. Ophthalmology, 1989, 96, 1659-1666.	5.2	23